Pliant Therapeutics to Participate in the Piper Sandler Healthcare Conference

Rhea-AI Summary

Pliant Therapeutics (Nasdaq: PLRX) will participate in the Piper Sandler 37th Annual Healthcare Conference, December 2–4, 2025. A fireside chat featuring Bernard Coulie, M.D., Ph.D. (CEO), Keith Cummings, M.D. (CFO) and Éric Lefebvre, M.D. (CMO) is scheduled for Thursday, December 4, 2025 at 12:30 p.m. ET.

Interested parties can access a live webcast via the company’s Investor Relations Events & Presentation page. A replay will be archived on the Pliant website for 90 days after the event.

News Market Reaction – PLRX

-4.97%

-4.97% Session close to close

In the Dec 1 session, PLRX declined 4.97%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlights Pliant’s participation in the Piper Sandler 37th Annual Healthcare Conf...

Analysis

This announcement highlights Pliant’s participation in the Piper Sandler 37th Annual Healthcare Conference, with senior leadership presenting on December 4, 2025 and a webcast archived for 90 days. In context, recent news has included discontinuation of the BEACON‑IPF program and promising Phase 1 oncology data, alongside reduced operating expenses and cash of $243.3M as of Q3 2025. Investors may watch for any incremental commentary from this conference, subsequent clinical updates, and further clarity on the company’s oncology‑focused strategy.

Key Figures

Conference dates: December 2–4, 2025 Fireside chat time: 12:30 p.m. Eastern Time Webcast replay window: 90 days

3 metrics

Conference dates December 2–4, 2025 Piper Sandler 37th Annual Healthcare Conference

Fireside chat time 12:30 p.m. Eastern Time Scheduled on Thursday, December 4, 2025

Webcast replay window 90 days Replay available on company website after event

Historical Context

5 past events · Latest: Dec 04 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Dec 04	Clinical data update	Positive	-15.6%	Interim Phase 1 PLN‑101095 data showed multiple responders and tolerability.
Dec 01	Conference participation	Neutral	-5.0%	Announcement of participation and webcast access for Piper Sandler conference.
Nov 06	Earnings and update	Positive	-6.7%	Q3 2025 results with lower expenses, reduced net loss and strong cash balance.
Aug 07	Earnings and pipeline	Negative	-1.2%	Q2 2025 results plus discontinuation of bexotegrast in IPF and restructuring.
Jun 27	Program discontinuation	Negative	-7.2%	BEACON‑IPF trial terminated after unfavorable safety and risk‑benefit profile.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent history shows several fundamentally positive or de-risking updates followed by negative price reactions, suggesting a pattern of weak sentiment or selling into news.

Recent Company History

Over the last six months, Pliant reported discontinuation of its BEACON‑IPF program on Jun 27, 2025, then reiterated that setback but highlighted promising PLN‑101095 oncology data. Q2 and Q3 2025 updates on Aug 7 and Nov 6 showed reduced operating expenses, lower net losses, and substantial cash of $243.3M. On Dec 4, 2025, interim Phase 1 data for PLN‑101095 showed meaningful responses yet the stock fell. Today’s conference participation announcement on Dec 1, 2025 fits a pattern of informational news amid ongoing portfolio transition.

Key Terms

integrin-based therapeutics

1 terms

integrin-based therapeutics medical

"a clinical-stage biotechnology company focused on the discovery and development of integrin-based therapeutics"

Integrin-based therapeutics are drugs or biologic treatments that target integrins, which are proteins on cell surfaces that act like Velcro and signaling switches to help cells stick to each other and respond to their environment. By blocking or activating these proteins, such therapies can change inflammation, tissue repair, cancer spread or clotting, so investors watch them as potential high-impact treatments that can create new markets, move clinical-stage valuations, and carry clinical and regulatory risk.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SOUTH SAN FRANCISCO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company focused on the discovery and development of integrin-based therapeutics, today announced its participation in the Piper Sandler 37^th Annual Healthcare Conference to be held December 2 – 4, 2025.

Bernard Coulie, M.D., Ph.D., President and Chief Executive Officer, Keith Cummings, M.D., Chief Financial Officer and Éric Lefebvre, M.D., Chief Medical Officer, will participate in a fireside chat on Thursday, December 4, 2025, at 12:30 p.m. Eastern Time.

Interested parties may access the live webcast of the fireside chat by visiting here or the Investor Relations’ Events & Presentation page of Pliant’s website. The webcast replay will be archived on the Pliant website for 90 days following the conclusion of the event.

About Pliant Therapeutics, Inc.

Pliant Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of integrin-based therapeutics. The Company’s lead program is PLN-101095, a small molecule, dual-selective inhibitor of α_vß₈ and α_vß₁ integrins, that is being developed for the treatment of solid tumors. In addition, Pliant has received regulatory clearance for the conduct of a Phase 1 study of PLN-101325, a monoclonal antibody agonist of integrin α₇β₁ targeting muscular dystrophies. Pliant’s early-stage platform includes preclinical research focused on tissue-specific delivery and internalization of drug payloads utilizing integrin receptor-binding molecules. For additional information, please visit: www.PliantRx.com. Follow us on social media X, LinkedIn and Facebook.

Investor and Media Contact:
Christopher Keenan
Vice President, Investor Relations and Corporate Communications
Pliant Therapeutics, Inc.
ir@pliantrx.com

FAQ

When will Pliant Therapeutics (PLRX) present at the Piper Sandler Healthcare Conference?

Pliant's fireside chat is scheduled for December 4, 2025 at 12:30 p.m. ET.

Who will represent Pliant Therapeutics (PLRX) at the December 2025 Piper Sandler conference?

Speakers are Bernard Coulie, M.D., Ph.D. (CEO), Keith Cummings, M.D. (CFO) and Éric Lefebvre, M.D. (CMO).

How can investors watch Pliant Therapeutics' (PLRX) Piper Sandler fireside chat live?

Investors can view the live webcast via Pliant’s Investor Relations Events & Presentation page.

Will Pliant Therapeutics (PLRX) provide a replay of the Piper Sandler presentation?

Yes. The webcast replay will be archived on the Pliant website for 90 days after the event.

What topics will Pliant Therapeutics (PLRX) executives discuss at the December 4, 2025 fireside chat?

The company indicated executives will participate in a fireside chat covering recent developments and outlook; specific topics will be discussed during the session.

Where can I find the Pliant Therapeutics (PLRX) webcast after the Piper Sandler conference ends?

The replay will be available on Pliant’s Investor Relations Events & Presentation page for 90 days following the event.